Genmab and ADC Therapeutics have entered an agreement to develop a new antibody-drug conjugate (ADC) product combining Genmab’s HuMax-TAC antibody and ADC’s PBD-based warhead and linker technology. The companies have completed in vitro and in vivo studies and now have the product ready for preclinical development for multiple cancer indications. Genmab and ADC will initially have an equal share in the product. ADC will lead and fund preclinical development. Prior to the IND submission, Genmab m...